Study on Trilaciclib for Preventing Blood Cell Loss in Patients with Limited-Stage Small Cell Lung Cancer

Sponsor: Pharmacosmos A/S

Sponsor score: 0

ClinicalTrials ID:NCT07473128

Provider View

This clinical trial is testing whether the drug trilaciclib can help protect blood cells in patients with limited-stage small cell lung cancer. Participants will be randomly assigned to receive either trilaciclib or a placebo to see if it is effective and safe.

Patient Parameters

Program Overview

The purpose of this study is to find out if trilaciclib can protect blood cells in patients with limited-stage small cell lung cancer. The trial will compare trilaciclib to a placebo to determine its effectiveness and safety. Participants will be randomly assigned to receive either trilaciclib or a placebo.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of limited-stage small cell lung cancer.
  • Have fully recovered from any previous cancer-related surgeries.
  • Have cancer that can be measured and evaluated through scans or tests.
  • Be willing to participate and sign a consent form agreeing to the study.

Exclusion Criteria

  • Have extensive-stage small cell lung cancer.
  • Have active heart disease.
  • Have known allergies to trilaciclib or related chemotherapy drugs like etoposide, carboplatin, or cisplatin.
  • Be pregnant or breastfeeding.

Locations

FACILITYZIPCITYSTATE
Pharmacosmos Investigational Site48073OaklandCalifornia

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.